Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Covington
Fuji
QuintilesIMS
Merck
Boehringer Ingelheim
Farmers Insurance
Cipla
Federal Trade Commission

Generated: June 18, 2018

DrugPatentWatch Database Preview

FEMARA Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Femara, and what generic alternatives are available?

Femara is a drug marketed by Novartis Pharms and is included in one NDA.

The generic ingredient in FEMARA is letrozole. There are twenty-four drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the letrozole profile page.
Drug patent expirations by year for FEMARA
Pharmacology for FEMARA
Drug ClassAromatase Inhibitor
Mechanism of ActionAromatase Inhibitors
Synonyms for FEMARA
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
1-Bis(4-cyanophenyl)methyl-1,2,4-triazole
112809-51-5
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE
4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE
4,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4 inverted exclamation marka-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1,2,4-TRIAZOL-1-YLMETHYL)DIBENZONITRILE
4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)-bisbenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4CA-0737
7LKK855W8I
809L515
A25380
AB0012832
AB00514009
AB00514009_10
AB00514009_11
AB00514009-05
AB00514009-07
AB00514009-08
AB00514009-09
AB07525
AB1009309
ABP001083
AC-1193
AC1L1GYT
AJ-45577
AK-59607
AKOS005145822
AN-6525
ANW-48664
API0024524
AX8041188
BC205693
BCP0726000213
BCP9000848
BDBM13061
Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-
BG0620
BIDD:GT0015
BIDD:PXR0130
Bio-0057
BPBio1_001331
BR-59607
BRD-K88789588-001-03-2
BSPBio_001209
C08163
C17H11N5
CAS-112809-51-5
CCG-100849
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CGS-20267 pound>>LETROZOLE
CHEBI:6413
CHEMBL1444
CPD000466343
CS-1776
CTK8B5413
D00964
D0C1WH
DB01006
DR001029
DSSTox_CID_3202
DSSTox_GSID_23202
DSSTox_RID_76924
DTXSID4023202
EN300-264820
EX-A965
F2173-0288
FEM-345
Femara (TN)
Femara (TN) (Novartis)
Femara, Letrozole
Femera
FT-0627797
GTPL5209
HE296649
HMS1571M11
HMS2051E08
HMS2089L22
HMS2098M11
HMS2233C23
HMS3369E11
HMS3393E08
HMS3651K05
HPJKCIUCZWXJDR-UHFFFAOYSA-N
HSDB 7461
HY-14248
I06-0022
J10423
KB-187805
KS-00000XA8
KS-1269
L0248
LEROZOLE
Letoval
LETRAZOLE
LETROF L LIL
LETROZ
Letrozol
letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
Letrozole [USAN:USP:INN:BAN]
Letrozole, >=98% (HPLC)
Letrozole, European Pharmacopoeia (EP) Reference Standard
Letrozole, pharmaceutical secondary standard; traceable to USP, PhEur
Letrozole, United States Pharmacopeia (USP) Reference Standard
LS-38788
MFCD00866241
MLS000759455
MLS001424038
MLS002584991
MLS006010040
NC00099
NCGC00016973-01
NCGC00016973-02
NCGC00016973-03
NCGC00016973-06
NCGC00257460-01
Novartis Brand of Letrozole
NSC-719345
NSC-759652
NSC719345
NSC759652
Pharmakon1600-01502354
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
Q-201291
QCR-225
RP29922
RTC-070977
S-4137
s1235
SAM001246649
SC-00402
SCHEMBL4331
SMR000466343
SPBio_003070
ST2405214
STL451047
TL8000371
Tox21_110719
Tox21_303572
UNII-7LKK855W8I
W-60273
Z1741968261
ZINC3778874

US Patents and Regulatory Information for FEMARA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms FEMARA letrozole TABLET;ORAL 020726-001 Jul 25, 1997 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for FEMARA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2006-03-02

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Deloitte
McKesson
Daiichi Sankyo
QuintilesIMS
Teva
Julphar
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.